Price Over Earnings Overview: AstraZeneca
Portfolio Pulse from Benzinga Insights
AstraZeneca's stock is trading at $71.26 after a 0.66% drop, with a P/E ratio of 47.5, higher than the pharmaceutical industry's aggregate P/E ratio of 35.72. This could indicate overvaluation or better future performance compared to its industry group.
June 27, 2023 | 3:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AstraZeneca's P/E ratio of 47.5 is higher than the pharmaceutical industry's 35.72, which could indicate overvaluation or better future performance.
AstraZeneca's higher P/E ratio compared to the industry average could indicate either overvaluation or better future performance. However, it is uncertain which scenario will play out, making the short-term impact neutral.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100